​So we will continue to build the bundle test portfolio, not only in Swasthfit, but also in super specialty segments. For example, how do we kind of give a seamless journey on cancer care or autoimmunity or reproductive diagnostics? So bundle test is an across the portfolio, across the spectrum kind of focus for us, not just restricted to a few tests and so on. So yes, on the whole bundle test portfolio contribution will move up in the years to come as well.